Because patients with ER-positive and ERBB2 (formerly HER2; OMIM 164870)–negative (ER-positive/ERBB2-negative) disease have continuous risk for several decades after primary diagnosis,4 it is important to examine the long-term survival impact of primary breast cancer tumor characteristics, including clinically used markers of breast cancer. This evidence concerns the gene ERBB2 and breast cancer.